GEHC GE HealthCare Technologies Inc.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · Nasdaq · SEC CIK 1932393 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.9%
TTM net income YoY-2.8%
TTM EPS YoY-2.1%
Revenue 3-yr CAGR3.9%
Net income 3-yr CAGR7.8%
Margins
Gross margin39.9%
Operating margin13.3%
Net margin10.0%
FCF margin8.7%
EBITDA margin14.8%
Returns
ROE19.9%
ROA5.8%
ROIC (approx.)13.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets69.1%
Debt / equity0.86x
Current ratio1.30x
Interest coverage6.60x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-0.7%
Payout ratio3.0%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20.62B | $19.67B | $19.55B | $18.34B | $17.59B |
| Gross profit | $8.25B | $8.21B | $7.92B | $7.18B | $7.17B |
| R&D expense | $1.26B | $1.31B | $1.21B | $1.03B | $816.00M |
| SG&A expense | $4.22B | $4.27B | $4.28B | $3.63B | $3.56B |
| Operating income | $2.76B | $2.62B | $2.44B | $2.52B | $2.79B |
| Interest expense | $440.00M | $504.00M | $542.00M | $77.00M | $40.00M |
| Pretax income | $2.77B | $2.58B | $2.36B | $2.51B | $2.88B |
| Income tax | $614.00M | $531.00M | $743.00M | $563.00M | $600.00M |
| Net income | $2.08B | $1.99B | $1.57B | $1.92B | $2.25B |
| EBITDA | $3.05B | $2.89B | $2.68B | $2.75B | $3.02B |
| EPS (basic) | 4.56 | 4.37 | 3.05 | 4.22 | 4.95 |
| EPS (diluted) | 4.55 | 4.34 | 3.03 | 4.22 | 4.95 |
| Dividends declared per share | 0.14 | 0.12 | 0.12 | — | — |
| Weighted avg. shares (diluted) | 458.00M | 459.00M | 458.00M | 454.00M | 454.00M |
| Balance sheet | |||||
| Cash & equivalents | $4.49B | $2.89B | $2.51B | $1.45B | $561.00M |
| Inventory | $2.23B | $1.94B | $1.96B | $2.15B | — |
| Current assets | $12.50B | $9.90B | $9.41B | $8.32B | — |
| PP&E, net | — | — | $2.14B | $2.00B | — |
| Goodwill | $13.49B | $13.14B | $12.94B | $12.81B | $12.89B |
| Intangibles | $1.13B | $1.08B | $1.25B | $1.52B | — |
| Total assets | $36.91B | $33.09B | $32.45B | $27.54B | — |
| Current liabilities | $9.11B | $9.55B | $8.98B | $7.19B | — |
| Short-term debt | $502.00M | $1.50B | $1.00B | $15.00M | — |
| Long-term debt | $9.49B | $7.45B | $8.44B | $8.23B | — |
| Total debt | $10.00B | $8.95B | $9.44B | $8.25B | — |
| Total liabilities | $26.31B | $24.44B | $25.14B | $17.95B | — |
| Shareholders' equity | $10.38B | $8.45B | $7.13B | $9.36B | $16.68B |
| Net debt | $5.50B | $6.06B | $6.93B | $6.80B | — |
| Shares outstanding | — | — | 455.34M | 100 | — |
| Cash flow statement | |||||
| Operating cash flow | $1.99B | $1.96B | $2.10B | $2.13B | $1.61B |
| Capital expenditure | $482.00M | $401.00M | $387.00M | $310.00M | $248.00M |
| Free cash flow | $1.50B | $1.55B | $1.71B | $1.82B | $1.36B |
| Investing cash flow | -$1.05B | -$914.00M | -$558.00M | -$398.00M | -$1.76B |
| Financing cash flow | $617.00M | -$573.00M | -$478.00M | -$822.00M | -$263.00M |
| Depreciation & amortization | $287.00M | $268.00M | $248.00M | $228.00M | $225.00M |
| Stock-based compensation | $130.00M | $125.00M | $114.00M | $67.00M | $76.00M |
| Dividends paid | $64.00M | $55.00M | $41.00M | $0 | $0 |
| Share buybacks | $200.00M | $0 | $0 | — | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.